

To the FDA:

RE: DOCKET NO. 98N-1265

I send this letter as a consumer of healthcare services to register my concern and disapproval of the Memorandum of Understanding as published by the FDA on January 21, 1999.

In its present form, the MOU, as well as the Compounding Section 503A of the Modernization Act, severely restricts the rights of the physicians and patients to obtain healthcare products from the provider of their choice. It also infringes on the rights of compounding pharmacists to serve the public's medical needs. As a healthcare consumer, there should be no restrictions to the delivery of a compounded medication prescribed for me, regardless of where I may live or may travel. The MOU must be amended!

Phone: (812) 645-3591

Signed: Danbar M

State of Residence: New York


Comments: I am one of thousands of women responding well to natural compound hormone treatment for menopause and osteoporosis. These compound pharmaceuticals, prescribed by my physician, keep my blood levels normal with no side effects.

98N-1265

C 4917

Libt 2

597I-N86



DOCKETS MANAGEMENT BRANCH (HFA-305)
FOOD AND DRUG ADMINISTRATION
5630 FISHERS LN RM 1061
ROCKVILLE MD 20857-0003

